Several antibody therapeutics developed for oncology and degenerative diseases that may be effective for treating HO are already FDA approved (bevacizumab, anti-VEGFA; ref. 223) or are in the final stages of FDA approval (tanezumab, anti-NGF; refs. 224, 225). Here, NGF is linked to neurodegenerative disease.